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The complex spectrum of cell types produced in mammalian hematopoiesis can be understood as the output of highly
combinatorial transcription factor action. The generation of multiple diverse combinations of transcription factors from the
common starting state of the hematopoietic stem cell must be explained through the cross-regulatory interactions of these
transcription factors at several levels. Here, the operation of such a network is addressed through a focus on murine T cell
development, where we have recently established regulatory linkages between GATA-3 and PU.1 and multiple other factors
essential to this differentiation pathway. The action of both essential/rate-limiting factors and factors with effects that shift
qualitatively with dose and time of action can be traced through the regulatory interaction network. Hypothetical models
are proposed to indicate the network nodes that are differentially activated in normal T cell lineage progression and in cells
diverted to other potential fates. © 2002 Elsevier Science (USA)
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Hematopoietic differentiation provides an illuminating
set of cases and principles for developmental biology as a
whole. It is a system in which a well-characterized group of
cells, the hematopoietic stem cells, continuously generates
at least 10 different progeny cell types in appropriate ratios
without benefit of pattern formation. Each cell type can be
distinguished experimentally not only by morphology, but
also by a distinctive, well-defined set of effector genes.
These features make hematopoiesis an excellent system in
which to discern mechanisms that establish cellular iden-
tity apart from mechanisms involved in spatial patterning.
It is one of the few postembryonic developmental systems
in which multipotent cells can be studied prospectively as
they make choices among competing developmental paths,
thus giving access to specification events against the back-
ground of a relatively stable postnatal microenvironment.
Furthermore, because outputs of hematopoiesis are migra-
tory, recirculating cells without any stable interaction
partners, the cellular identities in this system, once estab-
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All rights reserved.lished, must be maintained cell-autonomously. The regula-
tory mechanisms that “lock down” cellular properties can
be extremely robust, because some hematopoietic cell
types, such as lymphocytes, clearly preserve their proper-
ties through extensive lifetimes and a virtually unlimited
number of mitotic cycles. Hematopoiesis thus offers access
to the whole conversion process from the pluripotent he-
matopoietic stem cells to each differentiated blood cell
type, as they transition from one metastable, pluripotent
state to any of several other, committed regulatory states.
Key Features of Hematopoietic Development
Initial evidence suggested that individual cell types in
this system could be specified uniquely by particular tran-
scription factors that are each expressed in a lineage-
specific way. Over the past decade, certain transcription
factor gene knockouts have shown effects on particular
hematopoietic cell types that seemed surgically precise. A
key example is GATA-1 (NF-E1, Eryf1), which is a positive
regulator of a classical gene battery in erythroid cells.
Disruption of the GATA-1 gene completely and selectively
blocks the differentiation of erythroid cells (Pevny et al.,
1991). In a similar way, B cell development in vivo depends
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on three sequentially activated transcription factors, E2A,
EBF, and Pax5, which act as positive regulators of B cell
genes (reviewed in Reya and Grosschedl, 1998; Busslinger et
al., 2000). As in the case of GATA-1 in erythroid cells,
targeted mutation of any of these transcription factors gives
devastating effects which are highly selective for the B
lineage. Initiation of the B cell program, moreover, appears
to be triggered by a lineage-specific homodimeric form of
the bHLH class A factor E2A (Bain and Murre, 1998; Shen
and Kadesch, 1995). These examples raise the tempting
suggestion that each of the 10 odd hematopoietic differen-
tiation pathways might be directed by its own, similarly
dedicated transcription factor, and that the key to each path
of cell-type specification could be found in the onset of
expression of the main gene battery regulator for that
pathway.
In fact, something more complex must occur. Consider-
ation of other hematopoietic cell types and deeper investi-
gation of the erythroid and B cell cases argue that cell fate in
this system is defined by a different regulatory mechanism
than activation of an “instructive” factor, which first turns
on any particular lineage-associated set of effector genes.
First, key positive regulators are not generally cell-type
specific in their expression: they are shared among pairs or
small groups of cell types (Graf, 2001; Orkin, 2001; Ness
and Engel, 1994). For example, GATA-1 is expressed in
megakaryocytes, mast cells, and eosinophils, as well as in
erythroid cells. At a minimum, this means that cell types
need to be distinguished by combinations of factors. A
corollary is that single factors can only be “instructive” in
a tightly limited context.
Second, many of the key regulatory factors are members
of small multigene families, the members of which have
overlapping expression patterns and at least some ability to
regulate the same target genes. Thus, although cells cannot
complete erythroid differentiation in the absence of
GATA-1, there are some apparently committed erythroid
precursors to be found in GATA-1 mutant embryos, ex-
pressing an extensive set of erythroid genes under the
control of GATA-2 (Weiss et al., 1994). GATA-2 is a family
member that is expressed at high levels in stem cells, prior
to GATA-1 upregulation. GATA-2 cannot substitute for
GATA-1 completely to sustain erythroid development, but
this is at least in part due to its own distinctive develop-
mental downregulation in the erythroid lineage, not to an
inability to turn on erythroid genes.
Third, pluripotent hematopoietic precursors in adult
mammals are not a tabula rasa with respect to effector gene
expression. Instead, they chronically carry on a multilin-
eage gene expression program. Even at a single-cell level,
these cells express lineage-associated effector genes of sev-
eral cell types simultaneously (Hu et al., 1997). The tran-
scription factors of stem cells must therefore be sufficient
to activate transcription of many differentiation-associated
genes long before lineage choice and cell-type specification.
It follows that differentiation in this system must involve
mechanisms to select a subset of genes from within this
spectrum of accessible genes, stabilize their expression, and
downregulate irrelevant genes, all long after these transcrip-
tion units may have been activated initially.
Fourth, negative regulation as well as positive regulation
are critical for establishing the irreversibility of the differ-
entiation cascade. Factors such as Pax5, which is an essen-
tial positive regulator for B cell development (Nutt et al.,
1997), now appear to have their most unique roles as
negative regulators, direct or indirect, of competing differ-
entiation programs (Nutt et al., 1999; Rolink et al., 1999;
Chiang and Monroe, 1999). The negative regulatory events
are essential for pluripotent precursors to undergo commit-
ment to a particular cell fate, and these functions continue
to be required long after expression of cell-type-associated
genes is initiated (Nutt et al., 1999; Horcher et al., 2001).
Finally, in contrast to many embryonic systems, cell-type
specification in hematopoiesis is not the step that ulti-
mately determines the relative outputs of different hema-
topoietic cell types. These yields are strongly influenced by
lineage-specific proliferation and survival signals provided
by cytokines that are secreted variably, in a highly regulated
way, by the microenvironment. Every blood cell terminal
differentiation program includes lineage-specific prolifera-
tive checkpoints where the number of cells produced de-
pends on interactions with particular cytokines. As a result,
the expression of the genes encoding the lineage-specific
cytokine receptors becomes one of the most important
aspects of differentiation-linked gene expression for each
cell type. The existence of this environmental level of
control has another important consequence for the regula-
tory logic of hematopoietic differentiation: as long as some
precursors of each lineage are made, it does not matter if
there are more or less than the ideal. By removing the
penalty for specification errors, ex post facto growth regu-
lation by cytokines makes it possible for the hematopoietic
system to make use of complex, delicate regulatory mecha-
nisms for creating lineage divergence, which need not be
robustly predictable in output volume. This allows the
system to be rewarded evolutionarily for the diversity of
outcomes it can produce, even if it generates them with
some inefficiency.
These features of the hematopoietic developmental sys-
tem tell us that each of the 10-odd hematopoietic cell types
is generated not through the dominant influence of a
particular transcription factor but through the selective
activation of a distinct set of nodes in a large transcriptional
regulatory network. In this paper, we discuss the network
elements that are needed to guide precursors into one
particularly interesting differentiation pathway, the T lym-
phocyte pathway. This review integrates our own recent
findings (Anderson et al., 2002a,b) with published data that
provide evidence for combinatorial transcription factor con-
trol of cell-type specification and for two kinds of logic
relationships entailed by the use of certain transcription
factors in this system. We then present a provisional
assembly into a network architecture of key regulatory
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nodes that are implicated in the generation of T lympho-
cytes.
Combinatorial Transcription Factor Functions in
Hematopoietic Cell Types
Combinations of known transcription factors suffice to
distinguish among most hematopoietic differentiation pro-
grams. This is illustrated in Table 1, in which the results of
published gene disruption and overexpression experiments
are combined to describe each of nine hematopoietic differ-
entiation programs, starting from stem cells or well-
characterized oligopotent precursor cell lines, in terms of
its requirements for and sensitivities to different factors.
Differentiation pathways that are severely inhibited in
mutants of a particular factor are considered to require that
factor, and its normal effect is considered positive (shown in
the table as “Yes”). Differentiation pathways that are se-
verely inhibited when a factor is overexpressed are consid-
ered sensitive to that factor, and its effect is considered
negative (“No”). There are some necessary shortcuts in the
construction of this table. Any or all of the long-term
responses to Notch activation are combined under
“Notch.” Also, to put the table into terms that can be
related to target gene cis-regulatory sites and avoid issues of
family member overlap, transcription factors that are close
relatives in the same multigene family are combined here,
e.g., programs with requirements for GATA-1, -2, and/or -3
are all reported as “Yes” entries under the category of
GATA factors. Some differentiation programs both depend
on a factor and can be aborted by that factor at high levels,
and in the table these are designated “Yes/No.” These cases
are of particular interest for the subject of this work, and are
treated in detail below.
The main implication of Table 1 is that most hematopoi-
etic cell types do not have a unique positive regulator. It
follows that any of a number of different transcription
factors could in principle act as permissive/instructive
TABLE 1
Combinatorial Regulatory Definition of Hematopoietic Cell Types
Cell type
Gene family functions
SCL E2A/HEB GATA-1,2,3 Notch/HES-1 PU.1 (Spi-B) c-Myb Ikaros C/EBP
B cell N Y N* N Y/N* Y Y —
NK cell N? N Y — — ? Y —
T cell N* Y Y/N* Y Y/N* Y Y ?
Dendritic cell N —, Y† N*? Y* Y ? —, Y† ?
Macrophage N* N* N* N* Y Y — Y*
Neutrophil N* N* N* N? Y N* — Y
Eosinophil** ? ? Y* ? Y/N* ? —? Y*
Erythroid Y Y‡ Y N N* N* — N*
Megakaryocyte Y Y‡ Y Y* N? Y* — N?*
Stem cells Y Y‡ Y Y Y§ Y Y§ ?
Note. Except as indicated (asterisk), entries reflect functions at normal levels of expression, as determined by effect of gene disruption
or by manipulating levels of another gene product that normally acts as an inhibitor. Results obtained in vivo (transgenics, targeted
mutations) and in vitro (cell lines) are combined in this table. Y, Required for generation of that cell type in differentiation beyond
uncommitted precursor. “Y” boxes are shaded for ease of pattern recognition. N, Inhibitory for generation of that cell type (N*, at artificially
elevated concentration); —, neither essential nor inhibitory; Y/N*, essential at low level, inhibitory at high level; ?, no definitive evidence.
References: Effects of SCL: reviewed in Begley and Green, 1999; also Hoang et al., 1996; Valtieri et al., 1998; Chervinsky et al., 1999; Herblot
et al., 2000. Effects of E2A and HEB: reviewed in Bain and Murre, 1998; Engel and Murre, 2001; also Heemskerk et al., 1997; Barndt et al.,
1999; Yokota et al., 1999; Spits et al., 2000. Effects of GATA-1, -2, and -3: reviewed in Shivdasani and Orkin, 1996; Orkin, 2001; also Ting
et al., 1996; Hendriks et al., 1999; Zhang et al., 1999; Nerlov et al., 2000; Matsumura et al., 2000; Chen and Zhang, 2001. Effects of Notch
and HES-1: Jones et al., 1998; Radtke et al., 1999, 2000; Pui et al., 1999; Tomita et al., 1999; Kaneta et al., 2000; Lam et al., 2000;
Varnum-Finney et al., 2000; Allman et al., 2001; Ohishi et al., 2001; Wilson et al., 2001; Koch et al., 2001; Jaleco et al., 2001. Effects of PU.1
and Spi-B: reviewed in Tenen et al., 1997; Fisher and Scott, 1998; also Quang et al., 1997; Yamada et al., 1997; Nerlov and Graf, 1998;
McKercher et al., 1999; Spain et al., 1999; Rekhtman et al., 1999; DeKoter and Singh, 2000; Anderson et al., 2000a,b; Colucci et al., 2001;
Hu et al., 2001. Effects of c-Myb: Rosson and O’Brien, 1995; Bellon et al., 1997; Allen, et al., 1999; Pearson and Weston, 2000. Effects of
Ikaros and family members: reviewed in Georgopoulos, 1997; Cortes et al., 1999; also Shortman et al., 1998; Nichogiannopoulou et al.,
1999. Effects of C/EBP family: reviewed in Tenen et al., 1997; Graf, 2001.
* Effects determined by overexpression (blocking or forcing differentiation).
† Certain subsets apparently require these factors, other do not (Spits et al., 2000; Shortman et al., 1998).
** Only limited data available for eosinophils. Mast cells are omitted because of inadequate data.
‡ Requirement inferred only for class A bHLH factor as dimerization partner for SCL/Tal-1.
§ Requirement in adult bone marrow only; role in colonization or long term self renewal.
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gatekeepers for a particular developmental program, de-
pending on the other transcription factors that are active in
the cell making the choice. For technical reasons, the
effects of multiple factors on lineage choice have been most
extensively explored for lymphocytes. T cell lineage choice
is grossly inhibited or eliminated by loss of any one of the
following: bHLH class A function, Notch1 function, c-Myb,
Ikaros, PU.1, or GATA-3, even when all the others are
present (see below). The differential importance of each of
these cooperating factors depends on its rarity in context.
Definitive adult-type hematopoietic stem cells, charac-
terized by their long-term survival, self-renewal, and stable
developmental multipotency, are shown to have complex
transcription factor requirements of their own (reviewed by
Dzierzak et al., 1998; also, Nichogiannopoulou et al., 1999;
Fisher et al., 1999; Begley and Green, 1999; North et al.,
1999; Mukouyama et al., 2000). Members of most of the
transcription factor families in Table 1 are essential or rate
limiting for the development or survival of these cells.
While the multipotent hematopoietic precursors in em-
bryos can have simpler requirements (Dzierzak et al., 1998),
most hematopoietic cells generated over a lifetime start
their differentiation by modulation of the already rich
regulatory environment indicated in Table 1.
Table 1 also shows that, while many cell types are often
affected similarly by any one perturbation, no two differen-
tiation programs have the same pattern of responses to
factor deprivation or overexpression. This is most striking
in view of the fact that the transcription factors listed in
Table 1 omit many, such as Runx1 and Pax5, that are
known to be important in particular hematopoietic cell
types. Thus, even with the loss of resolution caused by
grouping together responses to GATA-1 and to GATA-3, or
requirements for E2A and/or HEB, there is enough resolving
power left in the combinatorial effects of this subset of
known transcription factors to define each program
uniquely. In effect, we can imagine measuring the degree of
a cell type’s dependence on or inhibition by each transcrip-
tion factor along an independent axis in a multidimensional
regulatory space. Then, each hematopoietic cell type can be
described by a different, unique point in that multidimen-
sional space. The question of how such cells develop from a
common stem cell is ultimately answered by explaining
their trajectories as they fan out from a common starting
point through this regulatory space.
There is remarkably little direct evidence for the tran-
scription factor expression patterns of developmental inter-
mediates between stem cells and differentiated progeny.
Only in recent years have several groups reported charac-
terization of restricted but uncommitted progenitors at this
level (Kondo et al., 2001). The transcription factors ex-
pressed by such cells have been interpreted mostly in light
of the clusters of cell types that these precursors are known
to produce. For the most part, these identified precursors
appear to fall into categories: lymphoid precursors, myeloid
precursors (macrophage and granulocyte), erythromyeloid,
or erythromegakaryocytic precursors (Akashi et al., 2000;
Kondo et al., 1997). The abilities of a precursor to generate
progeny that cross category boundaries have remained con-
troversial (Rodewald et al., 1999; Radtke et al., 2000). Table
1, however, suggests an interesting prediction about such
precursors. This is that, if there is any immature cell type
that simultaneously expresses the functions needed by two
separate differentiation pathways, and as long as it happens
to avoid expressing functions antagonistic to those cell
types, then that immature cell should be able to act as a
precursor of both mature cell types. It should act as a
precursor for those cells even if they were not previously
known or guessed to be able to develop from a common
precursor. This is an illuminating prediction because it
reverses the usual way of looking at hematopoietic path-
ways. If the combinations of transcription factors expressed
in a precursor are sufficient to predict its developmental
potentials, then the main question is what transcription
factor combinations are possible. This question can be
answered in terms of molecular mechanisms that restrict
the combinations of transcription factors that can be coex-
pressed and their abilities, in context, to act on a particular
set of target genes.
Boolean and Qualitatively Dose-Dependent
Regulatory Effects
The independent effects of transcription factors become
constrained in combination, both in terms of the impact on
differentiation and in terms of their impacts on each other’s
activity. In some cases, the requirements for transcription
factors can be abstracted as simple binary decisions, but
this is not always true. First, these regulators can have
varying effects, according to dose, on the differentiation of
the cells that need them. The “Yes/No” entries in Table 1
indicate that the hematopoietic effects of overexpression
and the effects of gene disruption are not simple comple-
ments of each other. Thus, precise regulation of transcrip-
tion factor levels is important. Second, transcription factors
regulate each other’s expression and posttranslationally
alter each other’s DNA binding and transactivation activi-
ties. This makes certain combinations unstable and others
invisible, depending in detail on concentrations, affinities,
cofactors, and subcellular localizations. Existing data dis-
tinguish between two kinds of response to key transcription
factors in the differentiation of particular hematopoietic
cell types. Examples of a “Boolean” response, based on
simple “and” or “and not” logic, are contrasted in Fig. 1
with examples of responses that are qualitatively different
at different doses of factor activity.
Figure 1A diagrams the relationships between lymphoid
cells and related cell types in terms of responses/
requirements for two particularly well-studied functions:
the activities of the class A bHLH transcription factors
(E2A, E2–2, and/or HEB) and those triggered by Notch
system signaling (HES-1 and others). For lymphocytes, the
effects of these functions appear to be Boolean. T and B cells
absolutely require the bHLH functions and are produced in
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direct relation to the extent that these transcription factors
are available (Bain and Murre, 1998; Heemskerk et al.,
1997). Natural killer lymphocytes (NK cells) are absolutely
inhibited by these functions and thus require a bHLH
antagonist (in vivo, Id2) (Yokota et al., 1999). Similarly, T
cells absolutely require Notch signaling (in vivo, Notch1) to
initiate their differentiation, while B cells are absolutely
blocked in their differentiation by Notch1 signaling (Radtke
et al., 1999; Pui et al., 1999). Like T/NK precursors,
B/macrophage precursors can be directed in their differen-
tiation choices by bHLH:Id ratios (Kee and Murre, 1998),
completing the matrix in Fig. 1A. In some myeloid-
restricted contexts, Notch1 signaling may also be able to
act as a macrophage/dendritic cell fate switch (Ohishi et al.,
2001) (see legend to Fig. 1A).
In addition to this simple kind of relationship, however,
there is another type which is highly dependent on the dose
of the transcriptional regulatory function. This relationship
is diagrammed for effects of PU.1 and GATA factors on
lymphocyte, macrophage, and erythroid/megakaryocytic
differentiation in Figs. 1B and 1C. These are the cases in
which a transcription factor can be both essential and
inhibitory to differentiation of a particular cell type (cf.
Table 1). For the divergent Ets-family factor PU.1, some
expression is essential to B cell development as well as
to macrophage development (Scott et al., 1994, 1997;
McKercher et al., 1996). But while a high level of expression
enhances macrophage development, it severely inhibits B
cell development (DeKoter and Singh, 2000) (Fig. 1B). In
fetal T cell development, also, PU.1 is essential (Scott et al.,
1994; McKercher et al., 1996; Spain et al., 1999) but
severely inhibitory when overexpressed, as we have re-
cently shown (Anderson et al., 2002b). For the GATA
factors, GATA-3 is essential for T cell development from
the earliest stages (Ting et al., 1996; Hendriks et al., 1999).
Still, when overexpressed in hematopoietic stem cells, it
completely blocks T cell development as well as B cell and
myeloid development (Chen and Zhang, 2001) (Fig. 1C).
The mechanisms of action and interplay of these two
transcription factors in T cell development are analyzed in
detail in the companion paper (Anderson et al., 2002a).
High-dose inhibition of a developmental program implies
that high doses activate interfering functions, direct or
indirect. In certain cases, this may occur through rapid
activation of a competing developmental program. Since
many hematopoietic programs involve terminal differentia-
tion with complete mitotic arrest, premature commitment
to such a pathway would take precedence over a slower-
progressing developmental program such as that of T or B
lymphocytes. Another way that high doses of one factor can
inhibit is by making that factor act as a repressor on the
regulatory sequences of other needed transcription factors
or growth factor receptor genes. A well-studied case is that
of Pax5 (a.k.a. BSAP), normally an activator of transcription,
which at high doses binds low affinity sites where it acts
specifically as a repressor (Wallin et al., 1998).
A final way that overexpression of a transcription factor
can interfere with a developmental program is through
protein–protein interactions, off the DNA (Sieweke and
Graf, 1998), that in some cases neutralize other transcrip-
tion factors. Important examples of factors that have been
shown to interfere in this way are PU.1 and the GATA
factors, which mutually block each other’s functions
(Rekhtman et al., 1999; Zhang et al., 1999; Nerlov et al.,
2000; Matsumura et al., 2000). Similarly, some function
activated by Notch signaling can also antagonize the func-
tion of the bHLH factor E2A (Ordentlich et al., 1998; Pui et
al., 1999). In the B cell case, Pax5 may act as an antagonist
of certain PU.1 functions (Maitra and Atchison, 2000). Only
a few such cases have been studied in detail, but more are
likely to exist. Because of the profound combinatoriality of
cell fate decisions in hematopoiesis, any inhibitory effect of
one transcription factor on another required factor can
block one differentiation pathway, while leaving another,
less dependent on the second factor, readily accessible.
Such mutual interference is likely to be highly
concentration-dependent and thus set quantitative thresh-
olds of expression beyond which combinatorial positive
functions break down.
The dose-dependent qualitative effects of particular tran-
scription factors indicate that cell fates in hematopoiesis
are not only distinguished by the combinations of transcrip-
tion factors needed to bind cis-regulatory sites of key
cell-type-determining target genes. They may also be dis-
tinguished in terms of the effective avidities with which
those cis-regulatory sites can be bound by the needed
transcription factors. Where transcription factor cooperat-
ivity is important, there can be positive evolutionary value
to maintaining weak, nonconsensus target sequences in
the binding sites for individual factors, thus guaranteeing
expression only when factor/factor interactions stabilize
enhancer occupancy. Avidity can also be influenced opera-
tionally by the availability of context-dependent coopera-
tive factors, and/or by the accessibility of the target site(s)
in chromatin. These conditions, like the need for regulatory
partners that may be sensitive to inhibition, are noteworthy
because they are likely to change over time in the course of
differentiation.
Path Dependence of Developmental Roles of Key
Hematopoietic Transcription Factors
Qualitative dose-dependence of developmental pathways
on transcription factors increases the complexity of hema-
topoietic differentiation processes beyond the simple ab-
straction implied in Table 1. The actual trajectory of a
differentiating cell through regulatory space, from hemato-
poietic stem cell to various combinatorially defined end
states, clearly depends on a network of time-dependent
interactions, not just the presence of an adequate checklist
of regulatory components. The order and duration of tran-
scription factor action contributes to lineage choice as well
as the level. A case in point is the effect of PU.1 overex-
pression on eosinophil development. PU.1, expressed tran-
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siently, can be helpful to induce expression of a C/EBP
factor that is needed in eosinophil development, but eosin-
ophil development also depends on GATA-1 expression,
which is shut off if PU.1 expression is maintained (Nerlov
and Graf, 1998). In the companion paper, we present evi-
dence that the timing of GATA-3 action in T cell develop-
ment is similarly critical (Anderson et al., 2002a). Any
model of a regulatory network for hematopoietic cell-type
specification must account for the mechanisms that open
and close the temporal windows for permitted activity.
In general, transcription factor loss-of-function or overex-
pression blocks a particular pathway when it results in
some forbidden state of transcription factor imbalance.
While such effects need not reproduce the pathways taken
by normal precursors—the blocked cells may not shift to
another developmental option—determination of the basis
for these forbidden states can reveal the constraints that
probably do shape real developmental programs. Transcrip-
tion factors that shift their functions qualitatively accord-
ing to dosage are particularly sensitive probes of time-
dependent features of a differentiation program. We can use
them to define the paths of allowed regulatory change that
lead to the various end states. This has been particularly
illuminating in the case of the T cell lineage choice by
multipotent precursors in the thymus, as described below.
T Cell Development as a Fate Determination
Model
T cell development is one of the hematopoietic pathways
in which cell type decisions are most experimentally acces-
sible. This is because, before hematopoietic precursors can
FIG. 1. Distinct modes of transcription factor action in hematopoietic cell-type specification, dose response effects. (A) Effects of bHLH
class A factors (E2A, HEB) and Notch1 signaling response factors in specification of lymphocytes: contrast to cell types with which they
share common progenitors. Roles of these factors in T and B cell development can be abstracted as a formal binary truth table. Axes
represent the range from absolute requirement for a factor (positive value) to developmental inhibition by that factor (negative value). For
the effects of the bHLH and Notch1 on T and B cell development, see text. For other cell types depicted, certain effects are less polarized.
Dendritic cells (DC) are heterogeneous and origin and function, and only some types require bHLH factors (Spits et al., 2000). Notch1
activity is not essential for macrophage, NK cells, or DC cells (Radtke et al., 2000), but Notch pathway activation enhances NK precursor
development at the expense of B cell precursors (Jaleco et al., 2001) and can facilitate DC cell differentiation while inhibiting macrophage
differentiation (Ohishi et al., 2001). (B, C) Dose-dependent effects of PU.1 (B) and GATA family factors (C) in B and T cell development as
compared with macrophage and erythroid development. The figues schematically portray the ability of the four cell types mentioned to
develop in the complete absence of the factor (extreme left of axis), at a low and/or temporally modulated level of the factor (middle of axis),
or when the factor is highly and/or chronically overexpressed (extreme right of axis). In (C), for T, B, and myeloid cell development, the
GATA factor referred to is GATA-3 (Chen and Zhang, 2001), while for erythroid cell development, the GATA factor referred to is GATA-1.
GATA-1 overexpression also blocks myeloid cell development. The responses of macrophages to PU.1 activity (B) and of erythroid cells to
GATA-1 activity (C) correspond to the “Boolean” responses to bHLH and Notch functions in lymphocyte development in (A).
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generate T cells, they must first segregate themselves from
most other hematopoietic differentiation by migrating to
the thymus (or in some cases, the intestinal epithelium). By
the time they arrive, these cells have lost erythroid and
most myeloid potential but are still uncommitted to the T
cell pathway. They remain able to give rise to myeloid-like
dendritic cells (DC), NK cells, and possibly even B cells
(Shortman et al., 1998; Ikawa et al., 1999; Michie et al.,
2000; Wilson et al., 2001). The last choices between T and
non-T fates occur in the thymus, at stages that can be
defined by cell surface markers as shown in Fig. 2 (DN1,
DN2, DN3, DP). The first landmark in this process is the
initial concerted establishment of a T cell gene expression
pattern, i.e., specification, which occurs at the DN2 stage
FIG. 2. Summary of T cell developmental stages: effects of transcription factor mutants. (A) A summary of phenotypically distinct stages,
developmental branch points, and checkpoints in T cell development. Also indicated are the stages at which development is arrested by
loss-of-function mutations in any of the indicated genes. Major developmental transitions are indicated by the italicized phrases in boxes
below the progression of stages. At the top of the figure, mutations that have been tested for specific effects on T cell development are
indicated in bold italics. Cell types at the successive stages are characterized by common abbreviations: DN, double negative for CD4 and
CD8 expression; DP, doubly positive for both CD4 and CD8 expression; ISP, immature single positive, i.e., immature cells that express CD8
without CD4 or high levels of surface TCR, which are intermediates between DN and DP stages; NK, natural killer cell; DC, dendritic cell;
Mac, macrophage. At the far right of the figure, the most mature T cell types are indicated by their coexpression of CD4 with high levels
of cell-surface T cell receptor (TCR) or by coexpression of CD8 with high levels of TCR. Lymph Pre, putative common lymphoid precursor
or T/NK/DC precursor. L/M Pre, putative common lymphoid/myeloid precursor. Different subsets of DN cells are distinguished as
DN1–DN4 on the basis of expression of the cell-surface markers CD44 and CD25 (not shown); for full description, see Haks et al. (1999).
The “DN1 subset” is actually developmentally heterogeneous; properties of subsets within this population are tentatively assigned to
“Lymph Pre,” to “NK, DC,” and to “other” based on further characterization (see Rothenberg et al., 1999; Anderson et al., 2002a for details).
Note that cells after specification, in the DN2 stage, still have some ability to differentiate to non-T fates, such as NK or DC. The figure
also indicates the stage at which endogenous PU.1 expression is finally shut off (endog PU.1) (Anderson et al., 1999) and the stage beyond
which rare survivors in PU.1/ thymus populations appear to be able to differentiate without constraint (Relief of block in PU.1/; Spain
et al., 1999). (B) Schematic summary of effects of PU.1 and GATA-3 overexpression in fetal liver-derived precursors attempting to undergo
T cell differentiation in fetal thymus organ culture. Data are from Anderson et al. (2002a,b). Curves follow an arbitrary scale using slope
to indicate cell recoveries at each stage relative to the previous stage, taking into account the changes in steady-state cell number between
stages in normal controls. A downturn can indicate failure to proliferate, where proliferation is normal, or failure to differentiate normally
from one stage to the next. After a downturn, a flat curve indicates no further loss relative to controls; a rising curve indicates some
compensatory recovery. The figure juxtaposes these transcription factor overexpression effects with periods where growth and survival of
the cells are dominated by IL-7R or by pre-TCR derived signals (Haks et al., 1999).
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(see Fig. 2 for description). This is followed by loss of all
remaining non-T developmental alternatives, or commit-
ment, which occurs by the DN3 stage. After this, the cells
can only survive if they succeed in rearranging at least one
of their T cell receptor (TCR) genes to encode a protein that
is expressed on the cell surface. If and only if the cells are
successful in this, they can pass the last important check-
point for our purposes here, “-selection.” This is a rapid
cascade of proliferation and physiological changes (Kruis-
beek et al., 2000; von Boehmer et al., 1999), with which the
cells finish their hematopoietic fate choices and enter the
strictly immunological phases of their development. The
easy identification of T cell precursors with predictable
differences in developmental potential enables a molecular
analysis of those differences to be made.
Figure 2 reviews the stages at which T cell development
appears to be arrested by the absence of certain key tran-
scription factors. Losses-of-function of different essential
factors each arrest this pathway at recognizably different
stages. Some of these functions are especially important to
establish the precursors that immigrate to the thymus in
the first place. In the absence of PU.1 or Ikaros, for example,
the fetal thymus is nearly empty of hematopoietic precur-
sors. However, these functions may be more dispensable
from -selection onward, for when a few mutant cells do
survive to this stage, they show little further impairment
(Spain et al., 1999; Wang et al., 1996). In the absence of
c-Myb or GATA-3, there are a few DN1-like cells in the
thymus, but it is not clear whether they have any relation
to T cell precursors; thus, the whole prespecification DN1
precursor subset may be missing (Allen et al., 1999; Ting et
al., 1996; Hendriks et al., 1999). Dominant-negative c-Myb
transgenes, expressed after T lineage specification, also
abort the proliferative burst that follows -selection (Pear-
son and Weston, 2000). In the absence of Notch-1 function,
precursors enter the thymus efficiently but differentiate
into B cells instead of T cells (Radtke et al., 1999; Wilson et
al., 2001;Koch et al., 2001). Notch-1 is acting here partially
FIG. 3. A provisional regulatory interaction network for T lineage specification. A transcription factor interaction network is diagrammed
from the impacts of PU.1 and GATA-3 overexpression in immature T cell precursors and from the effects of transcription factor mutants
in the literature. The diagram shows positive effects with arrowheads and negative effects (in a given context) by barred lines. To provide
for the effects of developmental context, the network includes three kinds of logic nodes (squares). Green boxes indicate direct interactions
that are demonstrated biochemically at the transcription factor/Ci-regulatory target interaction level. Blue boxes indicate actions needed
for survival of cells at a particular developmental stage. Striped boxes indicate as yet uncharacterized interactions that dictate whether a
given transcription factor effect will be permitted in a particular cellular context. Action at these nodes may be indirect. Data for the
existence of the conditional nodes come from our recent studies using fetal thymocytes and a DN3-like cell line, with some supporting
analysis of precursor-enriched fetal liver cells (Anderson et al., 2002a,b). Certain effects of GATA-3 and PU.1 overexpression are highly
context-dependent, including conditional nodes that are not detectably used at all in certain cell types. Also, PU.1 and GATA-3 appear to
act on certain target genes in a dual manner, with positive (sometimes essential) roles at physiological expression levels and negative effects
at higher levels or in different cellular contexts. These effects which switch direction are indicated by dashed lines (effects of PU.1 on IL-7R
and preT; effects of GATA-3 on Rag-1, -2). For effects of Id2 and SCL on the abilities of class A bHLH proteins to activate Rag gene and
preT expression, see Engel and Murre (2001) and Herblot et al. (2000). For regulation of the growth factor receptor c-kit by SCL/E2A and
c-Myb, see Vandenbark et al. (1996), Krosl et al. (1998), and Ratajczak et al. (1998). For regulation of GATA-3 by E2A/HEB and ZEB, see
Gre´goire and Rome´o (1999). For regulation of M-CSF-R expression by a PU.1/c-Jun/C/EBP complex antagonized by GATA-3, see Behre et
al. (1999) and Zhang et al. (1999).
FIG. 4. Operation of the regulatory interaction network in T lineage specification, commitment, and alternative lineage specification.
Four panels are shown to illustrate the nodes in the network that are likely to be active in different physiological conditions. (A) Early T
lineage specification. PU.1 and GATA-3 at low levels support expression of HES-1 and IL-7R, while avoiding mutual antagonism and
avoiding interference with the activation of Rag-1, Rag-2, and preT in response to class A bHLH proteins. PU.1 (or its family member Spi-B)
may help induce preT, while GATA-3 may aid in the sustained expression of c-kit in these early stages. However, during these stages,
precursors can be diverted to a macrophage or dendritic cell fate, possibly due to the sustained presence of PU.1. (B) T lineage commitment.
GATA-3 becomes dominant over PU.1 and shuts it off. This makes the various myeloid-like fates inaccessible, even if appropriate
costimulatory signals are provided. At this point, IL-7R expression declines (c-kit and SCL expression also decline, presumably due to the
disappearance of a cofactor that is not included in this network of interactions). This response has occurred by the time that the pre-TCR,
assembled in the earlier phases, begins to signal through the Ras and PKC pathways. It is not clear how PU.1 is turned off; one possibility
is that GATA-3 protein becomes more active without a substantial increase in RNA expression. E2A/HEB activity, which is critical for
success during -selection, can further sustain this period of relative GATA-3 predominance. (C) Perturbation of T cell development by
PU.1 overexpression. When PU.1 is overexpressed in early stage thymocytes or DN3-like SCID.adh cells, the ability of cells to progress
through T cell development is blocked by inhibition of Rag-1 and Rag-2 and by downregulation of c-Myb and HES-1. PU.1 can enhance the
expression of cell-surface Mac-1 and M-CSF-R on small subsets of thymocytes. In the cell line where prolonged responses can be measured,
a subset of the cells becomes Mac-1, and these cells also upregulate Id2 expression and exacerbate their repression of Rag-1, Rag-2, and
preT. (D) Perturbation of T cell development by GATA-3 overexpression. GATA-3 overexpression blocks the expression of myeloid-like
genes by subsets of thymocytes but also inhibits numerous functions needed for pre-TCR assembly as well as IL-7R. Without expression
of these genes, precursors cannot survive or undergo -selection. The upregulation of SCL and c-kit detected in certain thymocyte subsets
could signal some diversion toward a stem cell-like or megakaryocyte-like state.
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through HES-1, the loss of which has a more limited effect,
blocking the expansion and differentiation of precursors
through the DN23DN3 stages (Tomita et al., 1999; Kaneta
et al., 2000). Finally, since T cell precursors express both
E2A (E47 and E12) and HEB at high levels, single-gene
knockouts of these bHLH factors have only limited effects.
However, loss of E2A alone substantially shrinks the pool
of cells entering the DN2/3 pathway. Furthermore, overex-
pression of Id2 or Id3 massively blocks entry into the T cell
pathway, favoring development of NK cells instead. Even
overexpression of SCL (Tal-1), a class B bHLH factor, can
block T cell development, presumably by competitively
removing E2A or HEB into heterodimers (Heemskerk et al.,
1997; Barndt et al., 1999; Morrow et al., 1999; Herblot et al.,
2000; Engel et al., 2001; reviewed in Engel and Murre,
2001).
Just as there are points beyond which development can-
not proceed in the absence of particular transcription fac-
tors, there are time windows within which elevated con-
centrations of essential transcription factors block T cell
development. As shown in Fig. 2, PU.1 expression normally
declines between the DN1 and DN2 stages and is then
turned off in the DN3 stage. Forced maintenance of PU.1
expression at levels higher than in normal DN1 precursors
leads to inhibition of T cell development and a block to
passage through the -selection checkpoint (Anderson et
al., 2002b). Thus, a factor that is necessary in the early
stages (see Fig. 2A) becomes an antagonist of T cell devel-
opment at slightly later stages, as shown in Fig. 2B. Another
factor that is needed at an early stage is GATA-3, which, in
contrast to PU.1, continues to be expressed throughout T
cell development. However, as we show elsewhere (Ander-
son et al., 2002a), precocious elevation of GATA-3 expres-
sion causes an even more severe disruption of early T cell
development, with a strong block to generation of DN2 and
DN3 cells (Fig. 2B). Later in T cell development, its effects
are markedly less severe (Anderson et al., 2002a). Compari-
son of Figs. 2A and 2B implies that GATA-3 is essential
even for some of the stages at which its overexpression can
be inhibitory. In other words, the impact of this transcrip-
tion factor at a given time must be highly dependent on its
exact level of expression. These effects, we propose, can be
understood as a result of the high degree of transcription
factor combinatoriality required for T cell development and
the cross-regulation of these transcription factors by one
another.
A Regulatory Network Model for Early T Cell
Development
In the companion paper, we show that many of the genes
affected by overexpression of PU.1 or GATA-3 help to
explain the high-dose perturbations of T cell development
by these factors (Anderson et al., 2002a). The target genes
provide clues to the different time windows in which the
process is sensitive to these two factors. As many targets
are themselves regulatory genes, they can be organized
provisionally into a network-like architecture with their
own separate and combined targets. Here, we discuss this
initial draft assemblage of regulatory relationships in a
broader context, considering its implications for develop-
mental plasticity and diverse lineage choices. The state of
the evidence currently is far too limited to provide a clear
view of all the mechanisms involved. The direct evidence
thus far is drawn from the right ends of the PU.1 and
GATA-3 dosage curves in Figs. 1B and 1C, not from the
physiological range. However, several principles emerge
from the provisional network proposed here, which are
useful as a framework for interpreting the choices between
lymphoid development and other hematopoietic fates.
Figure 3 shows the regulatory connections between PU.1,
GATA-3, and the target genes that we have identified in the
companion paper (Anderson et al., 2002a) and in previous
work (Anderson et al., 2002b). The results were obtained by
retroviral transduction of immature fetal thymocytes from
mice, or by transduction of a cell line resembling DN3-
stage thymocytes, namely SCID.adh cells (Carleton et al.,
1999), followed by quantitative RT-PCR analysis of tran-
script levels in transduced cells 24–48 h later. The figure
primarily tracks effects on genes known to be important for
the DN2 and DN3 stages of early T cell development, i.e.,
those genes needed to program a cell for success in passing
the -selection checkpoint. It is supplemented with two
sets of non-T cell genes that have also been monitored in
our work.
One set, including the macrophage colony-stimulating
factor receptor gene (M-CSF-R, c-fms) and the myeloid-cell
integrin Mac-1 (CD11b), was included in the analysis be-
cause of the direct relevance of these genes to an alternative
developmental pathway that is favored by PU.1 overexpres-
sion, namely a macrophage/dendritic (“myeloid”) cell fate
(Anderson et al., 2002b; DeKoter and Singh, 2000). At least
the dendritic cell form of this differentiation pathway is
known to remain accessible to thymocytes in vivo well into
the DN2 stage (see Fig. 2A) (Shortman et al., 1998; Lee et
al., 2001). Also shown in Fig. 3 are two genes associated
with the stem-cell state which are also used by megakaryo-
cytic cells, namely those encoding the bHLH class B tran-
scription factor SCL (Tal-1) and the “stem cell factor”
receptor, the tyrosine kinase transmembrane protein c-kit.
These genes are expressed in DN1 precursors in the thymus
but normally shut off at the DN2 and DN3 stages, respec-
tively. Although current evidence indicates that cells in the
thymus no longer realistically have stem-cell or
megakaryocytic options, these genes were of interest be-
cause GATA-3 overexpression in hematopoietic stem cells
can promote c-kit megakaryocytic cell development at the
expense of both myeloid and lymphoid development (Chen
and Zhang, 2001).
The first important point is that the essential T lineage
transcription factors tracked in this study are not regulated
independently of one another. Overexpression of GATA-3
reduces levels of PU.1 consistently, while overexpression of
PU.1 inhibits HES-1 (downstream of Notch-1), c-Myb, and
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in some contexts GATA-3 as well (not shown). Also, results
with the SCID.adh cell line demonstrate another, indirect
pathway through which PU.1 overexpression can interfere
with the transcriptional activity of essential class A bHLH
factors. In the SCID.adh cell line, PU.1 is normally absent,
but when introduced, it reproducibly upregulates expres-
sion of the bHLH antagonist Id2 in a dose-dependent way.
This effect is not evident in primary fetal thymocytes, but
it could fail to be detected there either due to the need for
more sustained exposure to high PU.1 levels or to the
relatively high background of Id2 expression in some fetal
thymocytes normally. Although GATA-3 has a different
spectrum of effects than PU.1, it appears to upregulate at
least one additional transcription factor that can also play a
role in inhibiting T cell development, SCL (Chervinsky et
al., 1999; Herblot et al., 2000), and GATA-3 may slightly
increase the ratio of Id2 to E47 (Anderson et al., 2002a). The
combination of SCL and Id2 could synergistically block
actions of class A bHLH transcription factor proteins, since
Id factors disrupt class A/class A dimers preferentially and
spare SCL/E2A dimers (Nielsen et al., 1996). These effects
on expression of other transcription factors are presumably
supplemented within the transduced cells with potential
protein/protein interactions involving the overexpressed
GATA-3 or PU.1 proteins, which can also be mutually
inhibitory if levels are sufficiently high, as discussed above.
Each of these inhibitory effects will have its own dose-
response curve, and these still remain to be determined in
the lymphoid precursor context. But network architecture
shown here already makes it clear that cross-regulation of
transcription factor genes constrains the combinations and
levels of these factors that may be stable.
“First-Draft” Network Regulatory Nodes That
Operate in Early T Cell Development
When cells are differentiating normally toward a T cell
fate, they express a characteristic set of “pro-T cell” (DN2/
DN3 cell) effector genes that include potential targets of
PU.1 and GATA-3 perturbation. The low levels of PU.1 and
GATA-3 that normally occur in these states presumably are
not sufficient to repress these genes. The proposed path-
ways that are likely to be active in this early normal state
are highlighted in Fig. 4A. Once specified, the cells express
IL-7R for short-term survival, Rag-1 and Rag-2 recombi-
nase components to start T cell receptor gene rearrange-
ment, and preT to form an armature for assembly with any
successful product of TCR gene rearrangement. If they
succeed in assembling TCR and preT in a pre-TCR, they
may qualify for -selection. At that point, a different set of
functions becomes prominent, as highlighted in Fig. 4B.
Such later-acting functions are most notably involved in
the response to the Src-family kinase/Ras/PKC signaling
cascade that is initiated by successful pre-TCR assembly
(Kruisbeek et al., 2000). The key functions of the DN2/DN3
phase of T cell development must not only create the
receptor structure that will trigger -selection, but also
shift the cell to a physiological state that allows it to
respond appropriately.
Implications of the “First-Draft” Network:
Architecture of Potential Lineage Plasticity
The ability of elevated levels of essential transcription
factors to interfere with expression of other essential tran-
scription factors implies that the early T cell regulatory
state may not be particularly stable. A likely consequence is
that some combinations of circumstances will lead to
failure or to specification change. One clear set of linkages
that can act as a lineage switch is highlighted in color in Fig.
4C. This illustrates an accessible pathway, based on our
findings with thymocytes and the DN3-like SCID.adh line,
through which PU.1 may be able to respecify T cell precur-
sors as macrophages or myeloid-like dendritic cells.
Our results (Anderson et al., 2002a,b), suggest a distinc-
tion between two classes of PU.1 overexpression effects:
those that interfere with T cell developmental progression,
and those that activate and commit the cell to a competing
myeloid-like program. PU.1 overexpression can turn on the
M-CSF-R and Mac-1 (CD11b) genes in a minor subset of
fetal E14.5 thymocytes (Anderson et al., 2002b). The thy-
mocyte response is most evident in a Thy-1 minority of
the cells, mostly DN1-type cells, and this indicates that the
response is limited by a developmental threshold. Using the
SCID.adh cell line system, where effects can be measured
2–14 days after transduction, additional consequences of
PU.1 expression can be measured. In SCID.adh cells, after at
least 48 h of PU.1 expression, a subpopulation begins to
express cell-surface Mac-1 (CD11b) and upregulates expres-
sion of the bHLH antagonist, Id2 (the unknown features
that distinguish this subpopulation are represented as an
“uncharacterized”-type regulatory node in Figs. 3 and 4).
This subpopulation concomitantly silences expression of
Rag-1, Rag-2, and preT as well (Anderson et al., 2002b).
Thus, even if PU.1 itself may act as a positive regulator of
preT (in fetal thymocytes; dashed line in Figs. 3 and 4), it
can also induce gene expression changes that eventually
have the consequence of shutting off preT expression (in
SCID.adh cells). Notably, there is cell-to-cell mosaicism in
Mac-1 induction even in the cell line, which is also seen in
clonal sublines (C. J. Dionne, M.K.A., and E.V.R., unpub-
lished data), suggesting that part of the gating mechanism
for this response also depends on physiological state. In the
transduced SCID.adh cells, Mac-1 and Id2 are tightly co-
regulated; and as noted before, elevated Id2 expression is
incompatible with T cell development. Id2 expression is
essential for NK cell development and common in myeloid
development but downregulated at an early stage in T cell
development. Thus, there is a threshold-setting physiolog-
ical variable in the cells which determines the ability of
PU.1 coordinately to turn on both certain myeloid cell-
surface proteins and also to act as a nuclear antagonist of
the T cell developmental program.
The nature of this switch variable is not known. A
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pathway that may very well be implicated, however, is the
Ras and/or Protein Kinase C pathway. These activators are
known to favor macrophage development from myeloid
precursors (Cross and Enver, 1997), possibly by upregulating
activity of c-Jun and/or C/EBP family transcription factors,
which collaborate with PU.1 to turn on myeloid genes such
as M-CSF-R (Behre et al., 1999). There is also evidence that,
at stages up to the DN2 stage, inappropriate cytokine
receptor activation can block T cell development and/or
divert lymphoid precursor cells to a myeloid fate (Yasuda et
al., 1997; Kondo et al., 2000). The cytokine receptors used
may be able to activate the Ras pathway. In the latest stages
of thymocyte differentiation, too, Ras pathway activation
can turn on the Id2 relative, Id3 (Bain et al., 2001), which is
not upregulated in the DN3-like SCID.adh cells by PU.1
(M.K.A., unpublished results). It will be interesting to
determine whether a similar pathway upregulates Id2 at
these earlier stages.
Results from our studies and from the recent literature
indicate that GATA-3 could be involved in a different
program of respecification, if expressed at too high a level
too early in T cell development. When introduced into
purified hematopoietic stem cells from bone marrow (Chen
and Zhang, 2001) or enriched stem cells from fetal liver (D.
Chen, personal communication), GATA causes not T lin-
eage differentiation, but megakaryocyte differentiation, at
the expense of both lymphoid and myeloid cell fates. In this
respect, it appears to be having effects that are interpreted,
in the stem cell context, as GATA-1 effects. The diversion
of precursors into an erythromegakaryocytic pathway could
certainly contribute to the drastic reduction of T lineage
differentiation from GATA-3-transduced fetal liver precur-
sors that we see in thymic organ culture (Anderson et al.,
2002a). The upregulation of SCL/Tal-1 and c-kit that is seen
in response to GATA-3 (Fig. 4D) would be consistent with
some cells shifting toward a c-kit megakaryocytic fate
(Chen and Zhang, 2001). Alternatively, GATA-3 could be
mimicking not GATA-1, but the stem-cell factor GATA-2,
and thereby causing the cells to dedifferentiate to an SCL,
c-kit stem cell-like condition. Upregulation of HES-1 and
ongoing expression of SCL and Myb in GATA-3-transduced
cells would support either a megakaryocytic or a stem
cell-lineage diversion in early T cell precursors.
Developmental Switches
If GATA-3 overexpression causes either of these re-
sponses in the earliest thymocytes, then the regulatory
context must change substantially enough between the
DN1 state and the DN3 state to block GATA-3 from having
such GATA-1- or GATA-2-like effects when retrovirally
introduced later in T cell development, when it is less
deleterious (Fig. 2B) (Anderson et al., 2002a). The context
dependence of the effects shown in Fig. 4 essentially moni-
tors the progression of the cells from uncommitted to
committed states. This presumably means altering the
population of cooperating transcription factors and coacti-
vators. In normal thymocyte development, as we have
indicated, SCL (Tal-1) and its cofactors, Lmo1 and Lmo2
(Herblot et al., 2000; Chervinsky et al., 1999), may be
among the diversionary cofactors that are shut off during
this interval. To prevent the signaling pathways activated
at -selection from diverting the cells to a myeloid fate, it
may be critical to shut off PU.1 itself.
One way that the balanced levels of GATA-3 and PU.1
may initially maintain T lineage potential is by antagoniz-
ing each other’s transdifferentiation activities. While well
studied in vitro, this kind of mechanism has yet to be
proven to be acting in natural, pluripotent hematopoietic
precursors: the protein levels at which PU.1/GATA factor
antagonisms are actually effective may be more relevant
after lineage commitment. The pronounced ability of
GATA-3 to downregulate PU.1 RNA expression, however,
raises the possibility that it could play a role in the natural
shutoff of PU.1 expression that occurs during the DN2-to-
DN3 transition (Figs. 4B and 4D). GATA-3 RNA levels do
not increase during this interval (Anderson et al., 2002a),
but this does not rule out an increase in GATA-3 activity
via protein stability or posttranslational modification,
which could be significant (Yamagata et al., 2000). Several
events that occur naturally around this time, just before and
during -selection, notably mimic the effects of GATA-3
overexpression in transduced thymocytes. First is the shut-
off of PU.1 expression, then the loss of IL-7R activity, and at
-selection itself, this is followed by an abrupt downregu-
lation of Rag-1, Rag-2, and preT (Kruisbeek et al., 2000).
The latter genes are turned on again in the postmitotic DP
cells, but in the immediate context of -selection, they do
not need to be transcribed: if a burst of GATA-3 hyperacti-
vation transiently repressed these genes at -selection, it
would not interfere with development.
One can speculate that key thresholds for selection of the
appropriate PU.1 and GATA-3 activities are set by the
concentrations of enhancer-specific, cooperative transcrip-
tional partners. The most relevant of these partners for T
cell development may not yet be defined. However, factor/
factor interactions could normally play a major role in
targeting GATA-3 and PU.1 to a subset of potential target
sites. Transcription factor occupancy of well-studied cis-
regulatory elements in hematopoietic cells is often highly
coordinate (Hernandez-Munain et al., 1998; Rothenberg and
Ward, 1996), suggesting that in vivo, key transcription
factors are maintained at levels that are not sufficient to
saturate all possible sites. At levels of expression that allow
for occupancy of a higher fraction of sites, these transcrip-
tion factors might activate inappropriate targets or act, with
different partners, as repressors. At each network node, the
cis-regulatory sites through which the key transcription
factors exert their impacts, the likelihood of site occupancy,
and the interactions with other transcription factors within
those enhancer modules will all converge to regulate the
precise dose and temporal responses of lymphoid progeni-
tors to GATA-3 and PU.1.
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